Angiotensin-converting enzyme inhibitors were introduced in Australia in the early 1980s (captopril in 1983 and enalapril in 1986), and first reported to have renoprotective properties in diabetic kidney disease in 1992 [26]. This evidence concerns the gene ACE and diabetic kidney disease.